Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03625323
Title	Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)
Acronym	TACTI-002
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Immutep S.A.
Indications	laryngeal squamous cell carcinoma oropharynx cancer head and neck squamous cell carcinoma oral squamous cell carcinoma lung non-small cell carcinoma hypopharynx cancer
Therapies	Eftilagimod alpha + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| GBR \| ESP \| AUS